Company / Net Income
Corcept Therapeutics Incorporated Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$99.7M
FY2025
5-year range
$94.2M / $141.2M
FY2021-FY2025
Trend
-29.4%
vs FY2024
Sector context
#43 of 216
Health Care
What the data says
Corcept Therapeutics Incorporated's net income of $100M is higher than 80% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$31M in FY2016 to $141M in FY2024.
Based on SEC 10-K filings.
$100M in FY2025 with a 5-year CAGR of +5.7%. Top quartile in the Health Care sector.
Declined from $106M to $100M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +5.7%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 216This company $99.7M Sector average $454.1M
▼
-78.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.7%, indicating consistent growth.
- In FY2025, net income decreased 29.4% year-over-year.
- Ranks #43 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $99.7M | -29.4% |
| FY2024 | $141.2M | +33.0% |
| FY2023 | $106.1M | +0.1% |
| FY2022 | $106.0M | +12.6% |
| FY2021 | $94.2M | +24.9% |
| FY2020 | $75.4M | -41.6% |
| FY2019 | $129.1M | +1486.3% |
| FY2018 | $8.1M | -93.7% |
| FY2017 | $129.1M | +511.4% |
| FY2016 | -$31.4M | -389.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026